Survival is associated with genetic variation in inflammatory pathway genes among patients with resected and unresected pancreatic cancer

Annals of Surgery

Volumn 257, Issue 6, 2013, Pages 1096-1102

  Reid Lombardo, Kaye M ^a   Fridley, Brooke L ^a   Bamlet, William R ^a   Cunningham, Julie M ^a   Sarr, Michael G ^a   Petersen, Gloria M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Inflammation; MAPKI8P1; NFKB; Pancreatic cancer; Single nucleotide polymorphisms; SOCS3; Survival

Indexed keywords

GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROSTAGLANDIN SYNTHASE; STAT1 PROTEIN; TRANSCRIPTION FACTOR GATA 3;

ADULT; AGED; ALLELE; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CHEMORADIOTHERAPY; CHRONIC PANCREATITIS; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HOST SUSCEPTIBILITY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALLELES; DISEASE PROGRESSION; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NF-KAPPA B; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RECEPTOR, IGF TYPE 1; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; SURVIVAL RATE;

EID: 84879101434     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318275b7e5     Document Type: Article

References (32)

1. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute; 2012. Available at: http://seer.cancer.gov/csr/1975-2009-pops09/, based on November 2011 SEER data submission, posted to the SEER web site. Accessed December 27, 2012.
2. Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer. 1995;76:1671-1677.
3. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10:1199-1210; discussion 1210-1211.
4. Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007;110:738-744.
5. Artinyan A, Hellan M, Mojica-Manosa P, et al. Improved survival with adjuvant external-beam radiation therapy in lymph node-negative pancreatic cancer: a United States population-based assessment. Cancer. 2008;112:34-42.
6. Fatima J, Schnelldorfer T, Barton J, et al. Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival. Arch Surg. 2010;145:167-172.
7. Kazanjian KK, Hines OJ, Duffy JP, et al. Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss. Arch Surg. 2008;143:1166-1171.
8. Miller RC, Iott MJ, Corsini MM. Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium. Int J Radiat Oncol Biol Phys. 2009;75:364-368.
9. Tsai S, Choti MA, Assumpcao L, et al. Impact of obesity on perioperative outcomes and survival following pancreaticoduodenectomy for pancreatic cancer: a large single-institution study. J Gastrointest Surg. 2010;14:1143-1150.
10. Yeo CJ, Cameron JL. Prognostic factors in ductal pancreatic cancer. Langenbecks Arch Surg. 1998;383:129-133.
11. Talamini G, Falconi M, Bassi C, et al. Incidence of cancer in the course of chronic pancreatitis. Am J Gastroenterol. 1999;94:1253-1260.
12. Boyle P, Maisonneuve P, Bueno De Mesquita B, et al. Cigarette smoking and pancreas cancer: a case control study of the search programme of the IARC. Int J Cancer. 1996;67:63-71.
13. Tanaka M, Okazaki T, Suzuki H, et al. Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome. Cancer. 2011;117:744-751.
14. Reid-Lombardo KM, Fridley BL, Cunningham JM, et al. Inflammation-related gene variants as risk factors for pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:1251-1254.
15. McWilliams RR, Rabe KG, Olswold C, et al. Risk ofmalignancy in first-degree relatives of patients with pancreatic carcinoma. Cancer. 2005;104:388-394.
16. The International HapMap Consortium. The International HapMap Project. Nature. 2003;426:789-796.
17. Seattle SNPs [database online]. Bethesda, MD: National Heart, Lung and Blood Institute (NHLBI); 2000.
18. NIEHS SNPs. NIEHS Environmental Genome Project [database online]. Seattle, WA: University of Washington; 2006.
19. Carlson CS, Eberle MA, Rieder MJ, et al. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet. 2004;74:106-120.
20. Graziadei IW, Schwaighofer H, Koch R, et al. Long-term outcome of endoscopic treatment of biliary strictures after liver transplantation. Liver Transpl. 2006;12:718-725.
21. Lesina M, Kurkowski MU, Ludes K, et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 2011;19:456-469.
22. Ebrahimi B, Tucker SL, Li D, et al. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer. 2004;101:2727-2736.
23. Falconer JS, Fearon KC, Plester CE, et al. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg. 1994;219:325-331.
24. Waeber G, Delplanque J, Bonny C, et al. The gene MAPK8IP1, encoding islet-brain-1, is a candidate for type 2 diabetes. Nat Genet. 2000;24:291-295.
25. Bonny C, Nicod P, Waeber G. IB1, a JIP-1-related nuclear protein present in insulin-secreting cells. J Biol Chem. 1998;273:1843-1846.
26. Yuan HY, Chiou JJ, Tseng WH, et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res. 2006;34:W635-W641.
27. Grabe N. AliBaba2: context specific identification of transcription factor binding sites. In Silico Biol. 2002;2:S1-S15.
28. Ursing BM, Van Enckevort FH, Leunissen JA, et al. EXProt-a database for EXPerimentally verified Protein functions. In Silico Biol. 2002;2:1-4.
29. Dong X, Javle M, Hess KR, et al. Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. Gastroenterology. 2011;139:464-473, 473 e1-e3.
30. Nair PN, De Armond DT, Adamo ML, et al. Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2. Oncogene. 2001;20:8203-8214.
31. Tomizawa M, Shinozaki F, Sugiyama T, et al. Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer. World J Gastroenterol. 2010;16:1854-1858.
32. Chae YS, Kim JG, Sohn SK, et al. RIPK1 and CASP7 polymorphism as prognostic markers for survival in patientswith colorectal cancer after complete resection. J Cancer Res Clin Oncol. 2011;137:705-713.